- Home
- NSTS vs BLRX Comparison
NSTS vs BLRX Comparison
Compare NSTS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | BLRX |
|---|---|---|
| Founded | 1921 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 12.6M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NSTS | BLRX |
|---|---|---|
| Price | $11.91 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 4.2K | ★ 12.3K |
| Earning Date | 05-13-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $256,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.73 | $2.28 |
| 52 Week High | $13.06 | $7.77 |
Technical Indicators
Market Signals| Indicator | NSTS | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.91 | 39.16 |
| Support Level | $11.43 | N/A |
| Resistance Level | $12.30 | $2.76 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 0.00 | 37.50 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.